public scoping meeting will be held at 7:30 p.m. on November 7, 1995 at the Naval Surface Warfare Center at White Oak, 10901 New Hampshire Avenue, in Silver Spring, Maryland. A short formal presentation will precede the request for public comments.

GSA and FDA representatives will be available at this meeting to receive comments from the public regarding issues of concern. It is important that Federal, State, and County Agencies, interested individuals and groups take this opportunity to identify environmental concerns and significant issues that should be addressed in the EIS. In the interest of available time each speaker will be asked to limit oral comments to five minutes.

Agencies and general public are also invited and encouraged to provide written comments in addition to, or in lieu of comments at the public scoping meeting. Scoping comments should clearly describe specific issues or topics regarding the FDA Headquarters development, which the commentator believes the EIS should address. Written statements concerning the alternatives should be post-marked no later than November 20, 1995, to Ms. Eva Hegedus, Portfolio Management (WPTP), National Capital Region, General Services Administration, 7th and D streets SW, Washington, DC 20407, Telephone (202) 708-8591; Fax (202) 708-7671.

Dated: October 16, 1995.

Jack Finberg,

Branch Chief, Portfolio Management (WPT). [FR Doc. 95–26264 Filed 10–20–95; 8:45 am] BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Proposed Data Collections Available for Public Comment and Recommendations

The Department of Health and Human Services, Office of the Secretary will periodically publish summaries of proposed information collections projects and solicit public comments in compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995. To request more information on the project or to obtain a copy of the information collection plans and instruments, call the OS Reports clearance Officer on (202) 619– 1053.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Projects: Application for Correction of Public Health Service Commissioned Corps Records—0937– 0095—Extension No Change—An application is submitted by present and former PHS Commissioned Corps officers to request correction of an error or alleged injustice in their personnel records. The information submitted is used by the Board for Correction to determine if an error or injustice has occurred and to rectify such error or injustice.

Annual Number of Respondents: 25; Average Burden per Response: four hours; Total Burden: 100 hours.

Send comments to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue SW., Washington, DC, 20201. Written comments should be received within 60 days of this notice.

Dated: October 16, 1995. Dennis P. Williams, *Deputy Assistant Secretary, Budget.* [FR Doc. 95–26180 Filed 10–20–95; 8:45 am] BILLING CODE 4150–04–M

Notice of the Final Meeting of the Commission on Research Integrity

Pursuant to P.L. 92–463, notice is hereby given of the final meeting of the Commission on Research Integrity. The proceeding is open to the public.

The meeting will be on Tuesday and Wednesday, October 24 and 25, 1995, at the Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, Room 17– 94. The Commission will meet from 8:30 a.m. until 5 p.m. on both days.

Space is very limited in this location. Therefore, interested parties are advised to call the Executive Secretary before the meeting to verify the date, place, and agenda, and, if they want to attend, place their name on a first-come, firstserved list.

The mandate of the Commission is to develop recommendations for the Secretary of Health and Human Services and the Congress on the administration of Section 493 of the Public Health Service Act, as amended by and added to by Section 161 of the NIH Revitalization Act of 1993.

The Commission will finalize its recommendations on a number of issues on research misconduct and integrity including a new definition of research misconduct, a research integrity assurance for institutions, a processes by which to respond to and monitor related administrative processes and investigations, and development of a regulation to protect whistleblowers. Recommendations will be directed at research institutions, professional societies, Federal agencies, whistleblowers, respondents to allegations of research misconduct, research scientists, and the scientific community in general.

Because of time constraints, individuals wishing to make a presentation are urged to do so in writing and send their statement to Henrietta D. Hyatt-Knorr, Executive Secretary, Commission on Research Integrity, Suite 700, 5515 Security Lane, Rockville MD 20852, (301) 443-3400 (phone), (301) 443-5351 (fax), or hhyatt@oash.ssw.dhhs.gov (internet). Persons wishing to make an oral presentation must contact the Executive Secretary prior to the meeting. Depending on the number of presentations and other considerations, the Executive Secretary will allocate a timeframe for speakers. Henrietta D. Hyatt-Knorr,

Executive Secretary, Commission on Research Integrity.

[FR Doc. 95–26094 Filed 10–20–95; 8:45 am] BILLING CODE 4160–17–P

Centers for Disease Control and Prevention

Hospital Infection Control Practices Advisory Committee; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Hospital Infection Control Practices Advisory Committee.

Times and Dates: 8:30 a.m.–5 p.m., November 13, 1995; 8:30 a.m.–3 p.m.,

November 14, 1995.

Place: CDC, Auditorium A, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The committee is charged with providing advice and guidance to the Secretary, the Assistant Secretary for Health, the Director, CDC, and the Director, National Center for Infectious Diseases (NCID), regarding the practice of hospital infection control and strategies for surveillance, prevention, and control of nosocomial infections in U.S. hospitals and updating of guidelines and other policy statements regarding prevention of nosocomial infections.

Matters To Be Discussed: The agenda will include review and discussion of public comments regarding the draft Guideline for the Prevention of Nosocomial Intravascular Device-Related Infections, review of the first draft of the Guideline for Infection Control in Hospital Personnel, and an update on CDC activities of interest to the Committee. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Julia S. Garner, Nurse Consultant, Hospital Infections Program, NCID, CDC, 1600 Clifton Road, NE, Mailstop A–07, Atlanta, Georgia 30333, telephone 404/639–6408.

Dated: October 17, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–26146 Filed 10–20–95; 8:45 am] BILLING CODE 4163–18–M

Advisory Committee for Injury Prevention and Control (ACIPC) and the Science and Program Review Work Group; Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

Name: Science and Program Review Work Group.

Time and Date: 1 p.m.–4 p.m., November 13, 1995.

Place: National Center for Injury Prevention and Control (NCIPC), Vanderbilt Building, Conference Room 1004, 2939 Flowers Road, South, Chamblee, Georgia 30341.

Status: Open to the public, limited only by the space available.

Purpose: The purpose of this work is to advise NCIPC on program and scientific activities.

Matters To Be Discussed: The Work Group will discuss future grant program announcements and Ad Hoc committee

reports. Agenda items are subject to change as priorities dictate.

Name: Advisory Committee for Injury Prevention and Control (ACIPC).

Time and Date: 9 a.m.–3:30 p.m., November 14, 1995.

Place: Holiday Inn at Lenox, 3377

Peachtree Road, NE, Atlanta, Georgia 30326. Status: Open to the public, limited only by

the space available.

Purpose: The Committee will continue to make recommendations on policy, strategy, objectives, and priorities including the balance and mix of intramural and extramural research; advise on the implementation of a national plan for injury prevention and control, the development of new technologies and their application; and review progress toward injury prevention and control.

Matters To Be Discussed: The Committee will meet to discuss (1) current and future issues in violence prevention, (2) reports from other agencies on violence prevention activities, (3) an update from the Director, NCIPC, and (4) a report of the Science and Program Review Work Group and the Family and Intimate Violence Prevention Subcommittee meeting, held in Des Moines, Iowa.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Mr. Thomas A. Bartenfeld, Acting Executive Secretary, ACIPC, NCIPC, Mailstop K–60, CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30341–3724, telephone 770/488– 4230.

Dated: October 17, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–26145 Filed 10–20–95; 8:45 am] BILLING CODE 4163–18–M

CDC Advisory Committee on the Prevention of HIV Infection; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: CDC Advisory Committee on the Prevention of HIV Infection.

Times and Dates: 8:30 a.m.–5 p.m., November 13, 1995; 8:30 a.m.–3 p.m., November 14, 1995.

Place: Corporate Square Office Park, Corporate Square Boulevard, Building 11, Room 1413, Atlanta, Georgia 30329.

Status: Open to the public, limited only by the space available.

Purpose: This committee is charged with advising the Director, CDC, regarding objectives, strategies, and priorities for HIV prevention efforts including maintaining surveillance of HIV infection and AIDS, the epidemiologic and laboratory study of HIV and AIDS, information/education and risk reduction activities designed to prevent the spread of HIV infection, and other preventive measures that become available.

Matters To Be Discussed: The Committee will be updated on the ongoing reorganization of CDC's HIV/AIDS prevention programs. Other discussions will center around current HIV prevention activities. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Connie Granoff, Committee Management Specialist, National Center for HIV, STD, and TB Prevention (proposed), 1600 Clifton Road, NE, Mailstop E–07, Atlanta, Georgia 30333, telephone (404) 639–8029. Dated: October 17, 1995. Julia M. Fuller, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–26147 Filed 10–20–95; 8:45 am] BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95C-0399]

United States Surgical Corp.; Filing of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that United States Surgical Corp. has filed a petition proposing that the color additive regulations be amended to provide for the safe use of D&C Violet No. 2 as a color additive in glycolide/ dioxanone/trimethylene carbonate tripolymer absorbable sutures for general surgery.

DATES: Written comments on the petitioner's environmental assessment by November 22, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. FOR FURTHER INFORMATION CONTACT: Ellen M. Waldron, Center for Food Safety and Applied Nutrition (HFS– 216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–606–0202.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 721(d)(1) (21 U.S.C. 379e(d)(1)), notice is given that a color additive petition (CAP 5C0248) has been filed by United States Surgical Corp., 150 Glover Ave., Norwalk, CT 06856. The petition proposes to amend the color additive regulations in § 74.3602 *D&C Violet No. 2* (21 CFR 74.3602) to provide for the safe use of D&C Violet No. 2 as a color additive in glycolide/dioxanone/ trimethylene carbonate tripolymer absorbable sutures for general surgery.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4 (b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for